Literature DB >> 12136557

Detection and documentation of DRG-relevant comorbidities using laboratory tests.

Michael H Wilke1, Mike Schenker, Georg Hoffmann.   

Abstract

Germany will soon begin per case payment by DRG, and preparations are in progress in most hospitals and insurance companies. The Academic Teaching Hospital Munich-Schwabing in Munich decided to explore coding strategies by considering the impact of diagnoses that could be detected by pathology tests. An Australian database was analysed. We detected "discriminating" diagnoses--that is, diagnoses that could be found in level A or B DRGs, and not in the respective lower severity DRG. After isolating 584 diagnoses, they were rated by a laboratory specialist, to determine whether they could be proved by pathology tests. 187 diagnoses were selected in this way. In the next step, theoretical cases were generated and grouped. 157 diagnoses were found to produce a switch to a higher DRG. The diagnoses, the DRGs and the respective laboratory tests were then arranged in a small MS-Excel program to allow comfortable browsing. The overall success rate of 84% shows that laboratory medicine can contribute to correct coding for DRGs.

Mesh:

Year:  2002        PMID: 12136557     DOI: 10.1071/ah020152

Source DB:  PubMed          Journal:  Aust Health Rev        ISSN: 0156-5788            Impact factor:   1.990


  3 in total

1.  [Identification and economic evaluation of anesthesiologic secondary diagnoses on the basis of intraoperative medication].

Authors:  D Brammen; V Rickert; T Esser; F Prätsch; R Röhrig; Th Hachenberg; U Ebmeyer
Journal:  Anaesthesist       Date:  2016-05-25       Impact factor: 1.041

Review 2.  The Cost-effective Laboratory: Implementation of Economic Evaluation of Laboratory Testing.

Authors:  Natasa Bogavac-Stanojevic; Zorana Jelic-Ivanovic
Journal:  J Med Biochem       Date:  2017-07-14       Impact factor: 3.402

3.  The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report.

Authors:  Ulrich-Peter Rohr; Carmen Binder; Thomas Dieterle; Francesco Giusti; Carlo Guiseppe Mario Messina; Eduard Toerien; Holger Moch; Hans Hendrik Schäfer
Journal:  PLoS One       Date:  2016-03-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.